SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM...
-- New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1...
As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. 333-191380...
FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.